|
KMID : 0360320010330050377
|
|
Journal of Korean Cancer Research Association
2001 Volume.33 No. 5 p.377 ~ p.384
|
|
|
Combination Chemotherapy with Mitomycin C, Vinorelbine, and Cisplatin (MVrP) in Patients with Advanced Non-Small Cell Lung Cancer
|
|
김훈구/Gun Gu Kim
이경원/이대환/황인규/심기식/이원섭/이종덕/장정순/황영실/이종석/Gyeong Won Lee/Dae Hwan Lee/In Gyu Hwang/Ki Shik Shim/Won Sup Lee/Jong Deog Lee/Joung Soon Jang/Young Sil Hwang/Jong Seok Lee
|
|
|
Abstract
|
|
|
PURPOSE:
A phase II study was conducted in patients with advanced non-small cell lung cancer (NSCLC) in order to evaluate the efficacy and toxicity of the combination chemotherapy regimen of mitomycin C, vinorelbine, and cisplatin (MVrP).
MATERIALS AND METHODS:
Between June 1996 and December 2000, fifty-nine patients with unresectable stage IIIB to IV, pathologically documented NSCLC were enrolled in this study. One cycle consisted of mitomycin C 10 mg/m2 i.v. day 1, vinorelbine 30 mg/m2 i.v. days 1 & 15, and cisplatin 80 mg/m2 i.v day 1 and the next cycle consisted of vinorelbine 30 mg/m2 i.v. days 29 & 43, and cisplatin 80 mg/m2 i.v day 29. Each cycle was alternated and treatments were repeated every 8 weeks.
RESULTS:
We were able to evaluate fifty-three of 59 patients. Objective responses were seen in 22 (41.5%) patients (CR 0%, PR 41.5%). The median duration of response was 13.7 weeks and the median time to progression was 17.7 weeks. The median overall survival was 45.6 weeks. There was a significantly longer survival seen in responders (p=0.041). The toxicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION:
This study suggests that a combination regimen of mitomycin C, vinorelbine, and cisplatin is relatively effective and well tolerated for the treatment of advanced NSCLC.
|
|
|
KEYWORD
|
|
|
Non-small cell lung cancer, Combination chemotherapy, Mitomycin C, Vinorelbine, Cisplatin,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|